Dose-response profile of acarbose in older subjects with type 2 diabetes

American Journal of the Medical Sciences

Volumn 319, Issue 5, 2000, Pages 334-337

  Mooradian, Arshag D ^a   Albert, Stewart G ^a   Wittry, Susan ^a   Chehade, Joe ^a   Kim, Joohee ^a   Bellrichard, Brenda ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acarbose; Aging; Elderly; Postprandial; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034044254     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9629(15)40761-x     Document Type: Article

References (19)

1. Hoffman J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 1990;17:561-6.
2. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35.
3. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-8.
4. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98: 443-51.
5. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995;18: 817-24.
6. Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrate inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994;17:20-9.
7. Schnack C, Prager RJF, Winkler J, et al. Effects of 8-wk alpha glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 1989;12:537-43.
8. Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997;20:687-91.
9. Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetic patients with α-glucosidase inhibition. Diabetes Care 1998;21:416-22.
10. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83: 1515-22.
11. Mooradian A, Neumann C. PRECOSE resolution of optimal titration to enhance current therapies (PROTECT) study: experience in the elderly. J Am Geriatr Soc 1997;45: S49.
12. Mooradian AD. Biology of aging. In: Rehabilitation of the aging and elderly patient. Felsenthal G, Garrison SG, Steinberg FU, editors. Baltimore: Williams & Wilkins; 1994. p. 3-10.
13. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
14. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988;35:214-43.
15. Carroll MD, Dresser CM, Johnson CL, et al. Dietary intake of persons 1-74 years of age in the United States. Advance data from vital and health statistics of the National Center for Health Statistics No. 6. Publication no. (HRA) 77-1250. Rockville (MD): Health Resources Administration, Public Health Service; 1977.
16. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997; 14(Suppl 3):S6-S11.
17. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscl Thromb 1992;12: 1336-45.
18. Wolever TMS. Assessing the antihyperglycemic effect of acarbose. Solid or liquid test meal? Diabetes Care 1998; 21:667-8.
19. Herman BL, Schatz H, Pfeiffer A. Continuous blood glucose monitoring: the acute effect of acarbose on blood glucose variations. Med Klin 1998;93:651-5.